Replacing maximum-tolerated medications with latanoprost versus adding latanoprost to maximum-tolerated medications: A two-center randomized prospective trial

Journal of Glaucoma

Volumn 12, Issue 4, 2003, Pages 347-353

  Gandolfi, Stefano A ^a,c   Rossetti, Luca ^b   Cimino, Luca ^a   Mora, Paolo ^a   Tardini, Mariagrazia ^a   Orzalesi, Nicola ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

^c Istituto di Oftalmologia   (Italy)

Author keywords

Combination therapy; IOP; Latanoprost 0.005 ; Tolerability

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DORZOLAMIDE; LATANOPROST; PILOCARPINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; LACRIMATION; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VISUAL IMPAIRMENT;

ADRENERGIC BETA-ANTAGONISTS; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MIDDLE AGED; PILOCARPINE; PROSTAGLANDINS F, SYNTHETIC; RETREATMENT; SINGLE-BLIND METHOD; SULFONAMIDES; THIOPHENES;

EID: 0141651931     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00061198-200308000-00009     Document Type: Article

References (16)

1. Alm A, Camras CB, Watson P. Phase III Latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997;41:105-110.
2. Emmerich KH. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomised study. Graefes Arch Clin Exp Ophthalmol. 2000;238:19-23.
3. Hoyng PFJ, Rulo A, Greve EJ, et al. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Surv Ophthalmol. 1997;41:93-98.
4. Shin DH, McCracken MS, Bendel RE, et al. The additive effect of latanoprost to maximum tolerated medications with low-dose, high-dose or no pilocarpine therapy. Ophthalmology. 1999;106:386-390.
5. Simmons ST, Samuelson TW for the Alphagan/Xalatan Study Group. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. Clin Ther. 2000;22:389-399.
6. Linden C, Alm A. Latanoprost and physostigmine have mostly additive ocular hypotensive effects in human eyes. Arch Ophthalmol. 1997;115:857-861.
7. Fristrom B, Nilsson SEG. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993;111:662-665.
8. Strier SE. The additive effect of latanoprost 0.005% in patients on maximally tolerated medical therapy. Clin Eye Vis Care. 1997;9:189-196.
9. DesMarchais B, Candal E, Weitzman M, et al. Effect of latanoprost as adjunctive therapy. Can J Ophthalmol. 2000;35:214-217.
10. Patelska B, Greenfield DS, Liebmann JM, et al. Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol. 1997;124:279-286.
11. Lee DA. Efficacy of brimonidine as replacement therapy in patients with open angle glaucoma or ocular hypertension. Clin Ther. 2000;22:53-65.
12. Gandolfi SA, Vecchi M. Serial administration of adrenergic antagonists and agonists ('pulsatile therapy') reduces the incidence of longterm drift to timolol in humans. Inv Ophthalmol Vis Sci. 1996;37:684-688.
13. Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health. 1993;83:711-716.
14. Alm A, Stjernshantz J and the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost once daily, evening or morning. A comparison with timolol. Ophthalmology. 1995;102:1743-1752.
15. Camras CB and the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147.
16. Watson P, Stjernshantz J and the Latanoprost Study Group. A six-month randomized double-masked study comparing latanoprost to timolol in open angle glaucoma and ocular hypertension. Ophthalmology. 1996;103:126-137.